From the Guidelines
Renalazine is not a recognized medication in current medical practice, and it is possible that the question is referring to ranolazine, an anti-anginal medication used for chronic angina. Ranolazine is an antianginal medication with minimal effects on heart rate and BP, and it inhibits the late inward sodium current and reduces the deleterious effects of intracellular sodium and calcium overload that accompany myocardial ischemia 1. The medication is currently indicated for the treatment of chronic angina, and its recommended initial dose is 500 mg orally twice daily, which can be uptitrated to a maximum of 1000 mg orally twice daily 1.
Some key points to consider about ranolazine include:
- A systematic review of randomized, controlled trials and a Cochrane meta-analysis concluded that the extended-release formulation of 500 mg or 1,000 mg of ranolazine is effective in reducing symptoms of chronic stable angina 1.
- Ranolazine does not improve outcomes of patients with chronic stable angina, independently from the ventricular function, as shown in the RIVER-PCI trial and the MERLIN trial 1.
- Ranolazine might be effective in patients with microvascular angina, as suggested by some small, proof-of-concept studies and a larger trial conducted in this specific population 1.
Without additional context about what condition you're seeking treatment for, I cannot provide specific medication recommendations. If you're concerned about a particular health condition, it's essential to consult with a healthcare provider who can recommend appropriate, evidence-based treatments tailored to your specific needs and medical history.
From the FDA Drug Label
Ranolazine is a racemic mixture, chemically described as 1-piperazineacetamide, N (2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (±)-. Ranolazine is a white to off-white solid. Ranolazine is soluble in dichloromethane and methanol; sparingly soluble in tetrahydrofuran, ethanol, acetonitrile, and acetone; slightly soluble in ethyl acetate, isopropanol, toluene, and ethyl ether; and very slightly soluble in water
Ranolazine is a medication, specifically a racemic mixture, with a chemical description of 1-piperazineacetamide. It is used to treat chronic angina. The medication is available as a film-coated, non-scored, extended-release tablet for oral administration.
- Empirical formula: C24H33N3O4
- Molecular weight: 427.54 g/mole
- Solubility: soluble in dichloromethane and methanol, sparingly soluble in tetrahydrofuran, ethanol, acetonitrile, and acetone, slightly soluble in ethyl acetate, isopropanol, toluene, and ethyl ether, and very slightly soluble in water 2 2 2
From the Research
Definition and Mechanism of Action
- Renalazine is not a recognized medical term, however, based on the provided studies, it is likely that the user is referring to Ranolazine, a medication used to treat chronic stable angina.
- Ranolazine works by inhibiting the late sodium channels in the heart, which helps to reduce the frequency of angina episodes and improve exercise capacity 3, 4, 5, 6, 7.
Clinical Applications
- Ranolazine is currently approved for use in chronic angina, and its therapeutic benefits include improving exercise capacity and reducing angina episodes without affecting hemodynamics 3, 4, 6.
- The medication has also been studied for its potential use in other cardiovascular conditions, such as arrhythmias, heart failure, and pulmonary arterial hypertension 4, 5, 7.
- Additionally, ranolazine has shown promise in treating conditions such as atrial fibrillation, diastolic dysfunction, and chemotherapy-induced cardiotoxicity 7.
Safety and Efficacy
- Ranolazine has been shown to be generally well-tolerated, with common adverse effects including dizziness, nausea, and constipation 3, 6.
- The medication has a minimal effect on the QTc interval, and clinical data have not shown a predisposition to torsades de pointes 4, 6.
- Long-term data indicate that ranolazine does not significantly increase the incidence of death or arrhythmia among those taking the medication 3.